Publication: Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
No Thumbnail Available
Identifiers
Date
2021-02-02
Authors
Shah, Jatin
Shacham, Sharon
Kauffman, Michael
Daniele, Patrick
Tomaras, Dimitrios
Tremblay, Gabriel
Casasnovas, Rene-Olivier
Maerevoet, Marie
Zijlstra, Josee
Follows, George
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p
Description
MeSH Terms
Adult
Aged
Aged, 80 and over
Drug Resistance, Neoplasm
Female
Humans
Hydrazines
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Patient Reported Outcome Measures
Quality of Life
Recurrence
Triazoles
Aged
Aged, 80 and over
Drug Resistance, Neoplasm
Female
Humans
Hydrazines
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Patient Reported Outcome Measures
Quality of Life
Recurrence
Triazoles
DeCS Terms
CIE Terms
Keywords
EQ-5D-5L, FACT-Lym, diffuse large B-cell lymphoma, disutility of adverse events, health state utility, health utility, health-related quality of life, patient-reported outcomes, selinexor